Home Tags Brentuximab Vedotin

Tag: Brentuximab Vedotin

Phase II Clinical Trial of Brentuximab Vedotin Combination Therapy in...

Based on encouraging data in patients with CD30-expressing relapsed or refractory diffuse large B-cell lymphoma or DLBCL, the most common type of aggressive non-Hodgkin Lymphoma...

First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

First Study to Evaluate Brentuximab Vedotin as Front-line Treatment Confirms Effective,...

A study published in the September 16, 2015 online edition of Blood, the Journal of the American Society of Hematology (ASH), reports that brentuximab...

Seattle Genetics Completes Enrollment for Phase III Trial Designed to Evaluate...

Seattle Genetics and its collaborator, Takeda Pharmaceutical, have completed patient enrollment in the open label, phase III ALCANZA (NCT01578499) clinical trial.  This randomized trial is...

Looking Ahead to 2020: Global Antibody-drug Market Prediction

Cytotoxic drugs used in the treatment of solid tumors and hematological malignancies have, over the last 50 years, changed the natural progression of these...

Phase II Trial Evaluates Brentuximab Vedotin in Systemic Lupus Erythematosus

A new phase II clinical trial designed to evaluate the safety and efficacy of brentuximab vedotin (Adcetris®; Seattle Genetics) in systemic lupus erythematosus also known...

Analysis of Phase III AETHERA Data Demonstrates Brentuximab Vedotin Consolidation Therapy...

Several new analysis of Phase III data from the AETHERA trial (NCT01100502) demonstrate that brentuximab vedotin (Adcetris®; Seattle Genetics) consolidation therapy significantly extends progression-free...

Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...

Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...

Multiple Data Presentations Support Seattle Genetics’ Antibody-Drug Conjugate Program Development Plans...

The 106th Annual Meeting of the American Association for Cancer Research (AACR) being held April 18-22, 2015 in Philadelphia, PA, included eight abstracts on...

FDA Grants Priority Review for Brentuximab Vedotin in the Post-Transplant Consolidation...

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (BLA) for brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA setting...